Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on January 30, 2017, covering events occurring on January 24, 2017. The company is incorporated in Delaware and operates from Tucker, Georgia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
Under Item 5.02, the company reported the departure of a principal officer:
- Curtis Dale, Interim Chief Financial Officer, tendered his resignation effective immediately on January 24, 2017.
- The company has initiated a search for a qualified replacement.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items beyond the executive departure.
Investor Verification Points
- Confirm the timeline for the appointment of a new Chief Financial Officer.
- Review subsequent filings for any impact of the CFO departure on financial reporting or operations.
- Verify the status of the interim CEO, Gary Wilcox, who signed the report.